Developing PBPK Model-Based Mechanistic IVIVCs for Long Acting Injectable Suspensions and Implants (U01) Clinical Trial Optional

Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional

This grant aims to improve prediction of food/drug interactions for high-risk oral drugs by using a lab model that mimics the gut to assess drug performance.

HHS-FDA$500,000Forecasted

Integrating Machine Learning with Computational Fluid Dynamics Models of Orally Inhaled Drug Products (U01) Clinical Trials Not Allowed

This grant aims to combine machine learning and computational fluid dynamics to improve generic inhaled drug development and approval through alternative bioequivalence studies.

HHS-FDAForecasted

Evaluating the Cutaneous Pharmacokinetics of Topical Drug Products Using Pharmacokinetic Tomography (U01 Clinical Trial Required)

This grant supports developing non-invasive imaging to measure how topical drugs penetrate the skin, aiming for a new way to test topical drug bioequivalence.

HHS-FDA$250,000Forecasted

Development of Models, New Approach Methodologies, and Biological Materials for Studying Human Health and Diseases (R21 Clinical Trial Not Allowed)

This grant funds innovative research to develop or improve broadly applicable models, materials, and methodologies for studying multiple body systems or diseases relevant to human health, excluding single disease or system studies.

HHS-NIH11Forecasted Feb 16, 2028$500,000Forecasted

Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)

Accelerate precision probiotic therapies by identifying person-specific features affecting probiotic responses to enhance clinical outcomes.

HHS-NIH11Due Jun 2, 2027